Quintiles Transitional Holdings (NYSE:Q) has tumbled 3.31% during the past week and has dropped 4.73% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.15%. Quintiles Transitional Holdings (NYSE:Q) has underperformed the index by 5.6% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Quintiles Transitional Holdings (NYSE:Q): The stock opened at $64.65 on Friday but the bulls could not build on the opening and the stock topped out at $64.99 for the day. The stock traded down to $63.36 during the day, due to lack of any buying support eventually closed down at $63.40 with a loss of -2.27% for the day. The stock had closed at $64.87 on the previous day. The total traded volume was 1,960,830 shares.
The company shares have dropped -12.82% from its 1 Year high price. On Jul 29, 2015, the shares registered one year high at $80.45 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $66.37 and the 200 Day Moving Average price is recorded at $65.83.
On the companys insider trading activities,The officer (EVP and COO) of Quintiles Transnational Holdings Inc., Gordon Kevin K sold 24,000 shares at $66.41 on June 9, 2016. The Insider selling transaction had a total value worth of $1,593,840. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Many analysts have stated their opinion on the company shares. Wells Fargo downgrades its rating on Quintiles Transitional Holdings (NYSE:Q). Analysts at the Wells Fargo have a current rating of Market Perform on the shares. The shares were previously rated Outperform. The rating by the firm was issued on May 12, 2016. Currently the company Insiders own 10.9% of Quintiles Transitional Holdings shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 32.18% . Institutional Investors own 88.72% of Quintiles Transitional Holdings shares. During last six month period, the net percent change held by insiders has seen a change of 32.18%.
Quintiles Transnational Holdings Inc. is a biopharmaceutical services company. The Company is a provider of biopharmaceutical development services and commercial outsourcing services. The Company is engaged in the development and commercialization of pharmaceutical therapies. It also offers therapeutic, scientific and analytical services to its biopharmaceutical and other healthcare customers. The Company offers its services through two segments: Product Development and Integrated Healthcare Services. Its product development segment is a contract research organization (CRO) and is focused on Phase II-IV clinical trials and associated laboratory and analytical activities. Its Integrated Healthcare Services segment provides services, including commercial services, such as contract pharmaceutical sales forces, and healthcare business services, such as phase research, market access and consulting, and health information analytics and technology consulting.